Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal with groundbreaking gene therapy company Spark Therapeutics ...

said chief executive Vas Narasimhan. The event comes just over a year after Novartis completed the dismantling of its diversified life sciences model with the spinout of generic and biosimilar ...

Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...

Speaking with members of the media on Friday, Narasimhan said the "FDA no longer deemed it necessary to hold an advisory committee meeting." "We think it's based on, you know, the overall data ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...